Last reviewed · How we verify
NCT07280559
Evaluation of AI-assisted LDCT Screening in Lung Cancer
NA trial testing AI-assisted Low-Dose CT Interpretation in Lung Cancer in 1,120 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Taipei Veterans General Hospital, Taiwan |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 1,120 |
| Start date | 11 December 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2031 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- AI-assisted Low-Dose CT Interpretation
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Taipei Veterans General Hospital, Taiwan
Who can join
Adults 40 to 74, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicenter pragmatic randomized controlled trial evaluates whether AI-assisted interpretation of low-dose CT (LDCT) improves lung cancer screening performance compared with standard reading. Eligible participants are randomized to AI-assisted or conventional interpretation. The study assesses diagnostic accuracy, efficiency, lung cancer incidence, mortality, recurrence, and smoking cessation outcomes. Results will inform the clinical utility and potential implementation of AI-assisted LDCT in routine screening practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07280559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Taipei Veterans General Hospital, Taiwan trials
Trials by the same sponsor.
- NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07280559 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07280559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing